MarkD.TolpinMD

Infectious Disease • Millburn, NJ

HIV/AIDS Medicine, Healthcare Associated Infections, Transplant/Immunocompromised States

Consultant (semiretired) global clinical/regulatory drug/device development:

Join to view full profile

Dr. Tolpin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tolpin's full profile

Already have an account?

Office
256 Glen Ave
Millburn, NJ 07041
Phone+1 973-379-5589

Fax+1 973-379-5312

Education & Training

Children's Hospital of PhiladelphiaFellowship, Pediatric Infectious Diseases, 1977 - 1979
Drexel University College of MedicineResidency, Pediatrics, 1975 - 1977
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1974

Certifications & Licensure

NJ State Medical License 1987 - 2019
American Board of Pediatrics Pediatrics

Publications & Presentations

PubMed

84 citations
Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial
Lynn A. Drake, Neil H. Shear, Jon P. Arlette, Richard Cloutier, Frederick W. Danbye
Journal of the American Academy of Dermatology. 1997-11-01
136 citations
Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant p...
Gerald McMahon, Paul H. Ehrlich, Zeinab A. Moustafa, Linda A. McCarthy, Diane Dottavio
Hepatology. 1992-05-01
26 citations
Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication.
Mostafa Nokta, Mark D. Tolpin, Paul I. Nadler, Richard B. Pollard
Antiviral Research. 1991-04-01